June 30, 2021, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco")  announced that the first-in-Class   drug candidate, Bi-specific recombinant fusion protein targeting human CD47and HER2 named IMM2902 received clinical trial approval from the National Medical Products Administration (NMPA).This is the third new drug product based on CD47 of ImmuneOnco entered the clinical stage of development, and it is the cutting-edge product  targeting CD47 and Her2 for immunotherapy of solid tumors, another major milestone for the company.

 "We are pleased to learn that our clinical trial application for IMM2902 has been approved by the NMPA. IMM2902 is a bi-specific molecule for binding CD47 and HER2, developed based on our MAB-TRAP technology platform. The high affinity activity of HER2 enables the molecule to bind preferentially to tumor cells. at the same time, it retains the advantage feature of avoiding binding to human red blood cells, the "Antigenic sink", which greatly strengthens the tumor-specific synergistic effect of double targets. "We believe that IMM2902  has promising clinical value." Dr. Tian Wenzhi, founder of the company, is confident in IMM2902 clinical development..